Literature DB >> 3950237

Sodium nuclear magnetic resonance imaging of myocardial tissue of dogs after coronary artery occlusion and reperfusion.

P J Cannon, A A Maudsley, S K Hilal, H E Simon, F Cassidy.   

Abstract

Nuclear magnetic resonance (NMR) imaging techniques have been applied to the observation of tissue sodium-23 in normal and ischemic canine myocardium. To produce a region of ischemia and infarction in the myocardium, in six dogs a coronary artery was subjected to 1 hour of surgical occlusion followed by 1 hour of reperfusion. The dogs were then killed and sodium-23 NMR images of the excised hearts were obtained using a high field NMR imaging system. These images were compared with tissue sodium contents measured by flame photometry. The regions of ischemic damage were clearly visible as areas of increased sodium NMR signal on the three-dimensional images. A good correspondence was found between the relative intensity of the sodium signals and the sodium contents of normal myocardium and myocardium subjected to coronary artery occlusion and reperfusion. The data suggest the feasibility of NMR sodium imaging to detect the location and extent of myocardial damage in patients with coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3950237     DOI: 10.1016/s0735-1097(86)80467-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  3 in total

1.  Sustained postinfarction myocardial oedema in humans visualised by magnetic resonance imaging.

Authors:  J C Nilsson; G Nielsen; B A Groenning; T Fritz-Hansen; L Sondergaard; G B Jensen; H B Larsson
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

Review 2.  Sodium MRI in human heart: a review.

Authors:  Paul A Bottomley
Journal:  NMR Biomed       Date:  2015-02-12       Impact factor: 4.044

3.  A scale to measure MRI contrast agent sensitivity.

Authors:  Rohan D A Alvares; Daniel A Szulc; Hai-Ling M Cheng
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.